Search

Your search keyword '"MCCASHLAND, TIMOTHY M"' showing total 154 results
Start Over Author "MCCASHLAND, TIMOTHY M"
154 results on '"MCCASHLAND, TIMOTHY M"'

11. Methotrexate (MTX) Plus Ursodeoxycholic Acid (UDCA) in the Treatment of Primary Biliary Cirrhosis*#

Author

Combes, Burton, Emerson, Scott S., Flye, Nancy L., Munoz, Santiago J., Luketic, Velimir A., Mayo, Marlyn J., McCashland, Timothy M., Zetterman, Rowen K., Peters, Marion G., Di Bisceglie, Adrian M., Benner, Kent G., Kowdley, Kris V., Carithers, Robert L., Jr., Rosoff, Leonard, Jr., Garcia-Tsao, Guadalupe, Boyer, James L., Boyer, Thomas D., Martinez, Enrique J., Bass, Nathan M., Lake, John R., Barnes, David S., Bonacini, Maurizio, Lindsay, Karen L., Mills, Scott A., Markin, Rodney S., Rubin, Raphael, West, Brian A., Wheeler, Donald E., Contos, Melissa J., and Hofmann, Alan F.

Published
2005
Full Text
View/download PDF

14. Review of Medical Management of Primary Biliary Cholangitis.

Author

Rajendiran, Govarthanan, Mankongpaisarnrung, Charoen, Olivera-Martinez, Marco A., and McCashland, Timothy M.

Abstract

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with presumed autoimmune etiology. Current treatment options include ursodeoxycholic acid, obeticholic acid, and fibrate, which target mainly cholestasis. There is no effective therapy against autoimmune or hepatic fibrosis components. We can still achieve adequate biochemical response with monotherapy or a combination of medications in non-cirrhotic and compensated cirrhotic PBC patients. Several criteria are available for risk stratification and assess treatment response. Liver stiffness measurement by transient elastography is also a useful tool for evaluating disease progression. Lack of treatment or inadequate response are predictors of poor outcome. There is a strong need for additional therapies for PBC. [ABSTRACT FROM AUTHOR]

Published
2021

20. Castleman’s Disease and Posttransplant Lymphoproliferative Disorder after Liver Transplant: 3-Year Follow-Up

Author

Jha, Lokesh K., Ulmer, Laura L., Olivera-Martinez, Marco A., McCashland, Timothy M., Fu, Kai, and Rochling, Fedja A.

Subjects
Article Subject, hemic and lymphatic diseases, virus diseases
Abstract

A 59-year-old male with a history of hepatitis C cirrhosis and history of hepatitis B exposure presented 8 months after orthotopic liver transplant (LT) with fever, fatigue, myalgia, night sweats, nonproductive cough, and shortness of breath. Bone marrow biopsy for pancytopenia was positive for Epstein-Barr virus (EBV) DNA. Lymph node biopsy for lymphadenopathy on imaging showed human herpes virus 8 (HHV8) associated Castleman’s disease. Treatment included valganciclovir, rituximab, and prednisone taper with eventual discontinuation. Quantitative HHV8 DNA was initially 611,000 DNA copies/mL and was later undetectable at 6 months following treatment and remained undetectable at 3-year follow-up.

Published
2018
Full Text
View/download PDF

24. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation

Author

Divisions of Gastroenterology and Pathology, University of Michigan Medical Center, Ann Arbor, MI ; 3912 Taubman Center, Ann Arbor, MI 48109-0362, Divisions of Gastroenterology and Pathology, University of Michigan Medical Center, Ann Arbor, MI, Division of Gastroenterology and Pathology, University of Nebraska Medical Center, Omaha, NE, Divisions of Gastroenterology and Transplant Surgery, Oregon Health Sciences University, Portland, OR, Division of Hepatology, University of Texas Southwestern Medical School, Dallas, TX, Fontana, Robert J., McCashland, Timothy M., Benner, Kent G., Appelman, Henry D., Gunartanam, Naresh T., Wisecarver, James L., Rabkin, John M., Lee, William M., Divisions of Gastroenterology and Pathology, University of Michigan Medical Center, Ann Arbor, MI ; 3912 Taubman Center, Ann Arbor, MI 48109-0362, Divisions of Gastroenterology and Pathology, University of Michigan Medical Center, Ann Arbor, MI, Division of Gastroenterology and Pathology, University of Nebraska Medical Center, Omaha, NE, Divisions of Gastroenterology and Transplant Surgery, Oregon Health Sciences University, Portland, OR, Division of Hepatology, University of Texas Southwestern Medical School, Dallas, TX, Fontana, Robert J., McCashland, Timothy M., Benner, Kent G., Appelman, Henry D., Gunartanam, Naresh T., Wisecarver, James L., Rabkin, John M., and Lee, William M.

Abstract

Bromfenac, a nonnarcotic analgesic nonsteroidal anti-inflammatory drug, was associated with reversible, minor elevations in serum aminotransferase levels during clinical trials. The aim of this study is to describe the clinical, laboratory, and histological features of 4 patients with severe bromfenac hepatotoxicity identified at 3 tertiary care centers participating in the US Acute Liver Failure Study Group. Bromfenac was administered for chronic musculoskeletal disorders to 4 women in therapeutic doses of 25 to 100 mg/d for a minimum of 90 days. All patients reported a prodrome of malaise and fatigue and presented with severe, symptomatic hepatocellular injury with associated hypoprothrombinemia. None of the subjects had underlying liver or kidney disease, and there was no evidence of a hypersensitivity reaction. Other identifiable causes of acute liver failure were uniformly excluded. Despite supportive measures, all the subjects developed progressive liver failure over 5 to 37 days, leading to emergency liver transplantation in 3 patients and death in 1 patient while awaiting transplantation. Extensive confluent parenchymal necrosis that appeared to begin in the central zones and was accompanied by a predominantly lymphocytic infiltrate was noted in all the livers examined. Nodular regeneration was seen in the 2 patients with a more protracted clinical course. Administration of therapeutic doses of bromfenac for greater than 90 days was associated with the development of acute liver failure leading to liver transplantation or death in 4 adult women. The poor outcomes observed in this series, coupled with the inability to identify individuals at risk for severe, idiosyncratic bromfenac hepatotoxicity, preclude further use of bromfenac in the medical community.

Published
2006

26. Outcomes in Patients Receiving High Dose Ursodeoxycholic Acid Are Not Dependent on Disease Status

Author

Imam, Mohamad, primary, Gossard, Andrea A., additional, Kowdley, Kris V., additional, Luketic, Velimir A., additional, Harrison, M. Edwyn, additional, McCashland, Timothy M., additional, Befeler, Alex, additional, Harnois, Denise M., additional, Jorgensen, Roberta A., additional, Petz, Janice L., additional, Keach, Jill C., additional, DeCook, Alisha C., additional, Enders, Felicity, additional, and Lindor, Keith D., additional

Published
2011
Full Text
View/download PDF

27. S1871 The Association of Low Level of Both Vitamin a and Retinol Binding Protein With the Liver Complications in Patients With Primary Sclerosing Cholangitis

Author

Treeprasertsuk, Sombat, primary, Jansen, Peter L., additional, Kowdley, Kris V., additional, Luketic, Velimir A., additional, Harrison, M. Edwyn, additional, McCashland, Timothy M., additional, Befeler, Alex, additional, Harnois, Denise M., additional, Jorgensen, Roberta A., additional, Keach, Jill C., additional, Schmoll, Jeff, additional, Hoskin, Tanya, additional, Thapa, Prabin, additional, Enders, Felicity, additional, and Lindor, Keith D., additional

Published
2010
Full Text
View/download PDF

29. T1869 The Changing Face of Primary Sclerosing Cholangitis

Author

Silveira, Marina, primary, Kowdley, Kris V., additional, Luketic, Velimir A., additional, Harrison, M. Edwyn, additional, McCashland, Timothy M., additional, Befeler, Alex, additional, Harnois, Denise M., additional, Jorgensen, Roberta A., additional, Keach, Jill C., additional, and Lindor, Keith D., additional

Published
2009
Full Text
View/download PDF

44. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation

Author

Trail, Kynan C., primary, McCashland, Timothy M., additional, Larsen, Jennifer L., additional, Heffron, Thomas G., additional, Stratta, Robert J., additional, Langnas, Alan N., additional, Fox, Ira J., additional, Zetterman, Rowen K., additional, Donovan, Jeremiah P., additional, Sorrell, Michael F., additional, Pillen, Todd J., additional, Ruby, Elizabeth I., additional, and Shaw, Byers W., additional

Published
1996
Full Text
View/download PDF

49. Heterozygous α1-Antitrypsin Phenotypes in Patients with End Stage Liver Disease.

Author

Eigenbrodt, Marsha L., McCashland, Timothy M., Dy, Rohert M., Clark, James, and Galati, Joseph

Subjects
LIVER diseases, LIVER disease diagnosis, HEPATITIS C virus, HEPATITIS C, VIRAL hepatitis, HEPATITIS viruses, TRYPSIN inhibitors, LIVER transplantation
Abstract

Objective: The objective of the study was to determine the prevalence and associations of abnormal α1-antitrypsin phenotypes in Caucasian adults with end stage liver disease with particular emphasis on heterozygous phenotypes and disease from hepatitis C virus. Methods: All patients (788) with end stage liver disease considered for liver transplantation from July 1990 to June 1996 in a referral-based university hospital transplant center (University of Nebraska Medical Center, Omaha, NE) comprised the study population. Data for the study population was determined by retrospective review of the transplantation database at the transplant center. Hepatitis C virus infection was determined by a second generation ELISA method, and α1-antitrypsin phenotyping was performed on agarose gel with serum quantitation using a Behring Nephelometer. Results: Among 683 Caucasian patients with severe liver disease, the prevalences of Pi ZZ, Pi MZ, and Pi MS were 0.4, 7.3, and 8.2%, respectively, compared with 0, 2.8, and 4.2% in the control population. The odds of having a heterozygous Z phenotype were significantly increased in Caucasian patients with hepatitis C virus (odds ratio (OR) = 4.3, 95% confidence interval (CI) = 2.1-9.0), alcoholic liver disease (OR = 5.0, 95% CI = 2.6-9.6), primary hepatic malignancy (OR = 7.4, 95% CI = 2.9-19.0), and cryptogenic cirrhosis (OR = 2.6, 95% CI = 1.1-6.3) compared with the control population. Caucasian patients with hepatitis C or B virus were 3.6 times more likely to have a heterozygous Z phenotype than a normal phenotype compared with patients with diseases of autoimmune etiology. Conclusion: This study provides evidence of an association of heterozygous Z α1-antitrypsin phenotype with end stage liver disease of several etiologies, not hepatitis C virus alone. [ABSTRACT FROM AUTHOR]

Published
1997

50. Attitudes and Expectations of 1995 Gastroenterology Graduates About Gastroenterology.

Author

McCashland, Timothy M., Zetterman, Rowen K., Ruby, Elizabeth I., McCashland, Courtney R., and Wigton, Robert S.

Subjects
GASTROENTEROLOGY, MEDICAL care, PHYSICIANS, MEDICAL personnel, INTERNAL medicine
Abstract

Objective: To learn more about current attitudes and expectations of recent (June 1995) graduates of gastroenterology fellowship programs, why they chose either a private practice or academic career, and what impact managed care or health care reform had in their decision. Methods: Between April and June 1995, an 8-page, 35-question survey questionnaire was mailed to graduating fellows and returned for evaluation. Results: Graduates believed managed care had an impact on job availability, but it was not a factor in their job choice. Forty percent of the respondents reported that finding a job was either difficult or very difficult. The majority of respondents (67%) are pursuing a career in private practice. Most private practice physicians (PP) trained in 2-yr programs whereas academic physicians (AC) trained for the most part in 3-yr programs. The principal criteria on which decisions regarding job selection were based were similar between the two groups: coworkers, geographic location, access to patient care, and ability to perform endoscopy. Respondents in PP and AC expected to work 50-70 h/wk, care for patients with similar diseases, and have ample time for family. They would choose GI again as a career and believed that there is a future in GI. Salary expectations varied markedly between the two groups, and AC physicians were more concerned about their future financial needs. Twenty percent of PP physicians and 71% of AC physicians plan to participate in clinical research. Conclusions: Recent graduates of gastroenterology fellowship programs continue to have high expectations of their future careers. Although some had difficulty finding a job and stated that, although managed care had an impact on the job market, it had not yet become a major factor in their job selection. [ABSTRACT FROM AUTHOR]

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results